Nov. 13, 2018 — Yet another blood pressure drug has been recalled because of fears of impurities added by a lab in China.
Drug company Sandoz says it has recalled one lot of losartan potassium hydrochlorothiazide tablets. The impurity, known as NDEA, was found in the drug’s key ingredient made by Zhejiang Huahai Pharmaceutical Co. in China.
The recalled drug can be identified as Losartan Potassium Hydrochlorothiazide, 100-milligram/25-milligram tablets in 1,000-count plastic bottles; NDC (National Drug Code) 0781-5207-10; Lot number JB8912; with an expiration date of 06/2020. This product was distributed nationwide to distributors after Oct. 8.
This latest recall follows several others announced since July, when the FDA announced the recall of five separate valsartan blood pressure drugs over possible NDEA and NDMA contamination. Many more were announced in August as the recall spread to Canada and the European Union. And earlier this month, a blood pressure drug known as irbesartan was recalled.
People with questions may contact Sandoz Inc. at 800-525-8747, Monday through Friday from 8:30 a.m. to 5 p.m. ET, or email [email protected] Contact your doctor or pharmacist to discuss alternative treatments. Patients who are on losartan should continue taking their medication, as they may be more likely to be harmed if the treatment is stopped without an alternative.
An earlier version of this story listed an incorrect description of the recalled drug. It can be identified as Losartan Potassium Hydrochlorothiazide, 100-milligram/25-milligram tablets in 1,000-count plastic bottles
WebMD Article Reviewed by Neha Pathak, MD on November 13, 2018
FDA.gov: “Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API).”
© 2018 WebMD, LLC. All rights reserved.
Share this Post